Panaxia Labs Israel Ltd (PNAX.TA)

9,800.00 +2,123.00 (+27.65%) At close: 02:24PM IDT

Panaxia Labs Israel Ltd

Bat Sheva 1
Lod 7120101
Israel
972 7 2274 4144
https://panaxia.co.il

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. David Segal Ph.D.	Founder & CEO & Director	600k	N/A	1975
Ms. Sigal Ben Eli	Chief Financial Officer	455k	N/A	N/A
Dr. Eran Goldberg Ph.D.	Chief Technology Officer	600k	N/A	N/A
Mr. Asi Rotbert	Chief Business Officer & Director	600k	N/A	1975
Mr. Assi Rotbart	General Manager	375k	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILA.

Description

Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally. It offers pharma-grade smokeless cannabis products, such as oral tablets, orodispersible tablets, sublingual tablets, oral oils, sublingual drops, solution for inhalation, pastilles, topicals, suppositories, and cannabis extracts in ethanol under the NAXIVA – PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus brands. The company was incorporated in 2005 and is based in Lod, Israel.

Corporate Governance

Panaxia Labs Israel Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.